SAN DIEGO, CA, November 14, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that Punit Dhillon, President and CEO, will be presenting at the 6th Annual Medical Device Investor Forum in Irvine, California.
6th Annual Medical Device Investor Forum
Hyatt Regency Irvine
17900 Jamboree Road
Irvine, California, USA 92614
November 15, 2011
4:50 pm PST
In its 6th year, the two-day Orange County based conference will bring together industry professionals and investors in an effort to build funding opportunities for medical device innovations. The forum is intended to open up discussion amongst professionals ranging from established business leaders and key investors to early stage startup medical device venture capitalists.
OncoSec will also be attending the American Israeli Medical Association (AIMA) BioMedTech Conference in Los Angeles, CA.
AIMA – BioMedTech Conference
Skirball Cultural Center
2701 Sepulveda Blvd.
Los Angeles, CA 90049
November 15, 2011
About OncoSec Medical Inc. OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.
* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.